Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents
作者:Allyn T. Londregan、Liuqing Wei、Jun Xiao、Nathanael G. Lintner、Donna Petersen、Robert G. Dullea、Kim F. McClure、Michael W. Bolt、Joseph S. Warmus、Steven B. Coffey、Chris Limberakis、Julien Genovino、Benjamin A. Thuma、Kevin D. Hesp、Gary E. Aspnes、Benjamin Reidich、Christopher T. Salatto、Jeffrey R. Chabot、Jamie H. D. Cate、Spiros Liras、David W. Piotrowski
DOI:10.1021/acs.jmedchem.8b00650
日期:2018.7.12
The optimization of a new class of small molecule PCSK9 mRNA translation inhibitors is described. The potency, physicochemical properties, and off-target pharmacology associated with the hit compound (1) were improved by changes to two regions of the molecule. The last step in the synthesis of the congested amide center was enabled by three different routes. Subtle structural changes yielded significant
描述了新型小分子PCSK9 mRNA翻译抑制剂的优化。通过改变分子的两个区域,与命中化合物(1)相关的效力,理化性质和脱靶药理作用得到改善。拥挤的酰胺中心合成的最后一步是通过三种不同的途径实现的。细微的结构变化导致药理学和脱靶范围的显着变化。这些努力导致鉴定具有适合体内评估的总体概况的7l和7n。在一项为期14天的毒理学研究中,7l的安全性优于铅7f。我们假设改善的安全性与7l与非翻译核糖体的结合减少以及由于7l脱靶蛋白质的低强度导致的转录选择性的明显改善有关。